Impact News +++ Nahost-Krieg belastet Börsen: DAX und Wall Street unter Druck - Hapag-Lloyd warnt (Aktiencheck) +++ HAPAG-LLOYD Aktie -4,14%

AKESO Aktie

>AKESO Aktienkurs

13.7 EUR +2.2% (TradegateBSX)

Ask: 13.9 EUR / 1000 Stück

Bid: 13.7 EUR / 366 Stück

Tagesumsatz: 294 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

AKESO Aktie über LYNX handeln

Intraday

1 Jahr

>AKESO Performance

1 Woche: +3,8%

1 Monat: +19,5%

3 Monate: +8,0%

6 Monate: -10,0%

1 Jahr: +62,7%

laufendes Jahr: +13,4%

>AKESO Aktie

Name:

AKESO INC. O.N.

Land:

China

Sektor:

Gesundheit

ISIN/ Wkn:

KYG0146B1032 / A2P200

Symbol/ Ticker:

4RY (Frankfurt)

Kürzel:

FRA:4RY, ETR:4RY, 4RY:GR

Index:

Webseite:

https://www.akesobio.com/

Profil:

Akeso Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative, therapeutic solutions for the treatment of various diseases, particularly relating ..
>Volltext..

Marktkapitalisierung:

12436.64 Mio. EUR

Unternehmenswert:

12119.15 Mio. EUR

Umsatz:

299.03 Mio. EUR

EBITDA:

-59.78 Mio. EUR

Nettogewinn:

-100.65 Mio. EUR

Gewinn je Aktie:

-0.11 EUR

Schulden:

549.31 Mio. EUR

Liquide Mittel:

180.88 Mio. EUR

Operativer Cashflow:

-60.37 Mio. EUR

Bargeldquote:

3.54

Umsatzwachstum:

20.7%

Gewinnwachstum:

-3.69%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

AKESO

Letzte Datenerhebung:

27.03.26

>AKESO Kennzahlen

Aktien/ Unternehmen:

Aktien: 919.97 Mio. St.

Frei handelbar: 77.29%

Leerverk. Aktien: -

Rückkaufquote: -1.7%

Mitarbeiter: 3035

Umsatz/Mitarb.: 0.08 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 29.39%

Bewertung:

KGV: -

KGV lG: 164.02

KUV: 38.54

KBV: 15.29

PEG-Ratio: -15.07

EV/EBITDA: -

Rentabilität:

Bruttomarge: 80.06%

Gewinnmarge: -33.66%

Operative Marge: -29.08%

Managementeffizenz:

Gesamtkaprendite: -7.07%

Eigenkaprendite: -14.4%

>AKESO Peer Group

Gesundheit, Antikörper- Behandlung, Autoimmunerkrankungen, Onkologie/ Krebs- Behandlung

>AKESO Chart & Kurs - Tradegate

>AKESO News

27.03.26 - 09:00	Research: UBS Lowers AKESO TP to HKD173.4 Due to Weaker-than-Expected 2H Last Year Results (AAStocks)
	Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

27.03.26 - 04:57	Akeso Reports Full-Year 2025 Financial Results (PR Newswire)
	HONG KONG, March 26, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2025 annual results, highlighting a year of comprehensive, strategic leaps across all facets of its business. Commercial Operations Enter a New Phase of Growth In 2025, Akeso achieved......

26.03.26 - 17:30	Results: AKESO Full-Year Loss Expands to RMB11.13 Billion (AAStocks)
	AKESO (09926.HK) announced its 2025 annual results, reporting revenue of RMB30.56 billion, an increase of 43.9% year-on-year. Gross profit reached RMB24.04 billion, up by 31%. The loss expanded from RMB5.15 billion in the previous year to RMB11.13 billion, primarily due to an increase of RMB2.56 billion in impairment losses on e......

25.03.26 - 03:42	Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab (PR Newswire)
	HONG KONG, March 24, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that it has received clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate Phase II clinical trials for AK146D1,......

16.03.26 - 06:42	Akeso shares rise as cancer drug candidate enters clinical trials (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

16.03.26 - 03:09	Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance (PR Newswire)
	HONG KONG, March 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has received Investigational New Drug (IND) clearance from the National Medical Products......

05.03.26 - 03:27	Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results (PR Newswire)
	HONG KONG, March 4, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the latest long-term survival analysis data from the China pivotal registrational Phase II study (COMPASSION-03/AK104-201) of cadonilimab as a monotherapy for patients with recurrent......

04.03.26 - 14:54	Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM) (PR Newswire)
	Collaboration will evaluate Akeso's cadonilimab in combination with INOVIO's INO-5412 (INO-5401 plus INO-9012) as a potential treatment for glioblastoma (GBM), the most common and aggressive form of brain cancer Novel combination therapy will be studied as part of the Phase II adaptive......

04.03.26 - 14:06	INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM) (PR Newswire)
	Collaboration will evaluate INOVIO's INO-5412 (INO-5401 plus INO-9012) in combination with Akeso's cadonilimab as a potential treatment for glioblastoma (GBM), the most common and aggressive form of brain cancer Novel combination therapy will be studied as part of the Phase 2 adaptive......

11.02.26 - 23:33	EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) \| DelveInsight (PR Newswire)
	The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb),......

11.02.26 - 10:06	Akeso′s IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications (PR Newswire)
	HONG KONG, Feb. 11, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that the National Medical Products Administration has approved the initiation of Phase II clinical trials for AK139, a first-in-class IL-4Rα/ST2-targeting bispecific antibody, across seven indications.......

06.02.26 - 03:30	Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer (PR Newswire)
	HONG KONG, Feb. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that ivonescimab, its global first-in-class bispecific antibody targeting PD-1 and VEGF, has been granted its fifth Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the......

29.01.26 - 05:54	Ivonescimab Included in FirstWord Pharma′s "The Drugs That Will Shape 2026" (PR Newswire)
	HONG KONG, Jan. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The Drugs That Will Shape 2026", providing an in-depth analysis of 20 key drugs poised to define the trajectory......

19.01.26 - 12:27	Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis (PR Newswire)
	HONG KONG, Jan. 19, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that its supplemental New Drug Application (sNDA) for gumokimab (AK111), a novel humanized anti-IL-17A monoclonal antibody for the treatment of active ankylosing spondylitis (AS), has been accepted for review by the......

19.01.26 - 05:45	Research: CICC Predicts HSI to Add ZIJIN GOLD INTL/ BEONE MEDICINES/ PICC P&C/ AKESO as New Constituents; STANCHART May Replace HANG SENG BANK (AAStocks)
	Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

16.01.26 - 04:24

Akeso Confident of Cancer Drug′s FDA Approval Odds (Bloomberg)

Chinese biopharmaceutical firm Akeso's CFO, Bing Wang, says he feels “pretty good” about the chances of receiving approval from US regulators for ivonescimab, the company's key cancer drug developed in partnership with US-based Summit Therapeutics. Wang speaks exclusively on Bloomberg: The China Show from San Francisco, where the marquee industry event hosted by JPMorgan is taking place. (Source: Bloomberg)...

14.01.26 - 04:57	Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer (PR Newswire)
	HONG KONG, Jan. 13, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), comparing cadonilimab plus chemotherapy against a PD-1 inhibitor plus......

07.01.26 - 03:54	Ivonescimab′s Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study (PR Newswire)
	HONG KONG, Jan. 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update in China for its internally developed, first-in-class PD-1/VEGF bispecific antibody, ivonescimab. The updated label......

31.12.25 - 08:00	Outlook: CICC, Everbright Securities Int'l Top Picks for Hong Kong Stocks (Table) (AAStocks)
	CICC released its outlook report for 2026, listing its top picks for Hong Kong stocks:StocksTENCENT (00700.HK)BABA-W (09988.HK)CHINA MOBILE (00941.HK)CNOOC (00883.HK)NTES-S (09999.HK)SMIC (00981.HK)ZIJIN GOLD INTL (02259.HK)BYD COMPANY (01211.HK)AKESO (09926.HK)CATL (03750.HK)HAIER SMARTHOME (06690.HK)SKB BIO-B (06990.HK) JIANGX......

12.12.25 - 03:36	Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab (PR Newswire)
	HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody. The......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das Gesetz ist nichts anderes als ein richtiges, von dem Wesen der Götter hergeleitetes Gebot der Vernunft, welches das, was ehrbar ist, gebietet, und das, was entgegensteht, verwehrt. - Marcus Tullius Cicero

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram